Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Prebiotic drink may tame After-Meal blood sugar spikes

NCT ID NCT06714552

Symptom relief Sponsor: University of Aberdeen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a prebiotic supplement called galacto-oligosaccharide (GOS) can lower blood sugar spikes after eating. Fifty healthy adults will drink either a GOS supplement or a glucose control beverage, and their blood sugar and insulin levels will be measured over several hours. The goal is to see if replacing some digestible carbs with this prebiotic can help prevent the sharp rises in blood sugar that are linked to diabetes and heart disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Galacto-Oligosaccharide (GOS) prebiotic supplement
What this could lead to
If it works, this could point toward a simple dietary supplement to help manage blood sugar spikes after meals, potentially reducing the risk of diabetes and heart disease.
What could go wrong
This is a small, early-stage trial in healthy adults, not people with diabetes. The effect may be small or not translate to real-world meals. It only tests a single drink, not long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Jan 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy Men or Women * Body Mass Index (BMI) 18.5-29.9 kg/m\^2 * Between 18 and 65 years of age * Compliant (i.e., understands and is willing, able, and likely to comply with the experimental procedure and safety guidelines) * Able to provide informed consent * Premenopausal women must have a regular cycle or be on hormonal contraception. Exclusion Criteria: * Diabetes mellitus (all types including gestational diabetes) * HbA1c result over the study limit \[healthy range of between 4% and 5.9%\] * Endocrine disease (e.g., Cushing's syndrome) * Any food allergy or intolerance, or following Vegan diet * Medications that increase blood glucose (e.g., steroids, protease inhibitors, antipsychotics, antihypertensives, statins, diuretics, nicotinic acid, etc.) * Medications that lower glycemia (e.g., anti-hyperglycaemics, insulin, beta- blockers, etc.) * Medication affecting glucose regulation, appetite, and/or digestion/absorption of nutrients, antibiotics * Major medical or surgical event requiring hospitalization in the previous 3 months * Pregnant or lactating * Participation in another clinical/supplementation trial or actively trying to reduce body weight * Unable to comply with experimental procedures and safety guidelines * Unable to give consent * Smokers * Travel during the study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperinsulinemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperglycemia hyperinsulinism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperinsulinemia Postprandial hyperglycemia

Contacts and locations

Locations

  • University of Aberdeen, Rowett Institute

    Aberdeen, AB25 2ZD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.